Goldman Sachs
MRTX

Goldman Sachs’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Goldman Sachs’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75,233
Closed -$4.42M – 6012
2023
Q4 		$4.42M Buy
75,233
+40,234
+115% +$2.26M ﹤0.01% 3269
2023
Q3 		$1.52M Sell
34,999
-6,156
-15% -$220K ﹤0.01% 3978
2023
Q2 		$1.49M Sell
41,155
-6,607
-14% -$272K ﹤0.01% 4077
2023
Q1 		$1.78M Sell
47,762
-244,936
-84% -$11M ﹤0.01% 3956
2022
Q4 		$13.3M Buy
292,698
+74,440
+34% +$4.82M ﹤0.01% 2317
2022
Q3 		$15.2M Sell
218,258
-2,229,202
-91% -$165M ﹤0.01% 2099
2022
Q2 		$164M Buy
2,447,460
+2,318,853
+1,803% +$147M 0.04% 475
2022
Q1 		$10.6M Sell
128,607
-104,492
-45% -$10.7M ﹤0.01% 2634
2021
Q4 		$34.2M Buy
233,099
+36,903
+19% +$5.73M 0.01% 1647
2021
Q3 		$34.7M Buy
196,196
+17,692
+10% +$2.85M 0.01% 1569
2021
Q2 		$28.8M Sell
178,504
-234,935
-57% -$37.7M 0.01% 1732
2021
Q1 		$70.8M Sell
413,439
-64,561
-14% -$12.8M 0.02% 891
2020
Q4 		$105M Sell
478,000
-82,103
-15% -$17.7M 0.03% 592
2020
Q3 		$93M Buy
560,103
+181,261
+48% +$24.8M 0.03% 610
2020
Q2 		$43.3M Sell
378,842
-66,488
-15% -$6.45M 0.01% 1067
2020
Q1 		$34.2M Buy
445,330
+124,044
+39% +$11.1M 0.01% 1122
2019
Q4 		$41.4M Sell
321,286
-30,864
-9% -$2.98M 0.01% 1296
2019
Q3 		$27.4M Buy
352,150
+66,009
+23% +$6.2M 0.01% 1552
2019
Q2 		$29.5M Sell
286,141
-19,688
-6% -$1.53M 0.01% 1552
2019
Q1 		$22.4M Buy
305,829
+228,312
+295% +$15.5M 0.01% 1775
2018
Q4 		$3.29M Sell
77,517
-19,092
-20% -$761K ﹤0.01% 3214
2018
Q3 		$4.55M Buy
96,609
+49,315
+104% +$2.75M ﹤0.01% 3059
2018
Q2 		$2.33M Sell
47,294
-123,015
-72% -$4.65M ﹤0.01% 3532
2018
Q1 		$5.23M Buy
170,309
+137,901
+426% +$3.83M ﹤0.01% 2859
2017
Q4 		$591K Buy
+32,408
New +$503K ﹤0.01% 4701
2017
Q3 		– Sell
-98,251
Closed -$359K – 6918
2017
Q2 		$359K Buy
98,251
+87,858
+845% +$337K ﹤0.01% 5359
2017
Q1 		$54K Buy
+10,393
New +$57K ﹤0.01% 6266
2016
Q4 		– Sell
-68,076
Closed -$450K – 7142
2016
Q3 		$450K Buy
68,076
+30,914
+83% +$165K ﹤0.01% 5144
2016
Q2 		$203K Buy
+37,162
New +$592K ﹤0.01% 5680
2015
Q1 		– Sell
-27,295
Closed -$506K – 7340
2014
Q4 		$506K Sell
27,295
-9,390
-26% -$158K ﹤0.01% 5266
2014
Q3 		$642K Sell
36,685
-13,164
-26% -$246K ﹤0.01% 5049
2014
Q2 		$997K Buy
49,849
+21,402
+75% +$413K ﹤0.01% 4691
2014
Q1 		$542K Buy
28,447
+1,600
+6% +$33.3K ﹤0.01% 5212
2013
Q4 		$446K Sell
26,847
-7,300
-21% -$125K ﹤0.01% 5383
2013
Q3 		$517K Buy
+34,147
New +$336K ﹤0.01% 5134

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's MRTX Position: Q1 2024 in Review

Goldman Sachs sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 75,233 shares — an estimated $4.42M sold.

Goldman Sachs first reported a position in MRTX in Q3 2013 and held it in 35 quarters. The position peaked at $164M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Goldman Sachs reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 75,233 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.42M.
  • Goldman Sachs first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 35 quarters.
  • Goldman Sachs's Mirati Therapeutics, Inc. Common Stock position peaked at $164M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.